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Insulin-like growth factor-I and its binding proteins in healthy
mothers and their newborns
Fatores de crescimento insulina-símile e suas proteínas ligadoras em mães sadias e seus
recém-nascidos
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ABSTRACT
Objective: To determine serum levels of insulin-like growth factor-
I, free insulin-like growth factor-I and its binding proteins in maternal
serum and in cord blood of two groups of newborns with different
birth weights. Methods: A group of 60 healthy pregnant women
and their respective neonates with birth weight ≥  2500g (group 1)
and another comprising 23 healthy pregnant women and their
respective neonates with birth weight ≤  2500g (group 2) were
studied. Maternal and neonatal blood samples were analyzed for
levels of insulin-like growth factor-I, free insulin-like growth factor-
I, binding protein-1 and binding protein-3 by radioimmunoassay.
Statistical analysis: Student’s t test and multiple regression
analysis. Values of p < 0.05 were considered statistically
significant. Results: The t test showed that maternal insulin-like
growth factor-I, neonatal insulin-like growth factor-I, and neonatal
binding protein-3 values were significantly higher in Group 1 than
in Group 2. In both groups maternal values were higher than those
of their neonates (p < 0.05). Multiple regression analysis showed
a positive correlation between neonatal anthropometric variables
and neonatal insulin-like growth factor-I. Maternal binding protein-
1 showed a negative correlation with neonatal insulin-like growth
factor-I and binding protein-3. There was a positive correlation
between maternal insulin-like growth factor-I and neonatal ratio
free insulin-like growth factor-I/total insulin-like growth factor-I.
Conclusion: The findings of this study suggest that insulin-like
growth factor-I and its binding proteins 1 and 3 play a role in the
regulation of late fetal growth in normal Brazilian pregnant women.
Keywords: Somatomedins; Carrier proteins; Pregnant women;
Infant, newborn; Birth weight
ORIGINAL ARTICLE
RESUMO
Objetivo: Determinar os níveis séricos do fator insulina-símile-I,
fator insulina-símile-I livre e suas proteínas ligadoras 1 e 3 em
soro materno e no cordão umbilical de 2 grupos de recém-nascidos
com diferentes pesos de nascimento. Métodos: Foram estudados
dois grupos de gestantes sadias: um grupo de 60 mães e seus
respectivos recém-nascidos pesando 2.500 g ou mais ao
nascimento (grupo 1) e outro (grupo 2), compreendendo 23 mães
e seus respectivos recém-nascidos pesando menos de 2.500 g ao
nascimento. Foram colhidas amostras de sangue materno e dos
recém-nascidos para análise dos níveis séricos de fator insulina-
símile-I, fator insulina símile-I livre e suas proteínas ligadoras 1 e
3 por radioimunoensaio. Análise estatística: Foi utilizado o test t
de Student’s e a análise de regressão múltipla. Valores de p <
0,05 foram considerados estatisticamente significativos. Resultados:
O teste t mostrou que os valores do fator insulina-símile-I materno,
do fator insulina-símile-I neonatal, e da proteína ligadora 3 se
achavam significativamente aumentados no grupo 1 em relação ao
grupo 2. Em ambos os grupos os valores maternos foram mais
elevados que os de seus recém-nascidos (p < 0,05). A análise de
regressão múltipla mostrou uma correlação positiva entre os dados
antropométricos dos recém-nascidos e o fator insulina-símile-I
neonatal. A proteína ligadora-1 materna mostrou correlação negativa
com o fator insulina-símile-I e a proteína ligadora-3 do recém-
nascido. Houve uma correlação positiva entre o fator insulina-símile-
I materno e a relação fator insulina-símile-I/fator insulina-símile-I
livre do recém-nascido. Conclusão: Os achados deste estudo
sugerem que o fator insulina-símile-I e suas proteínas ligadoras
desempenham um papel na regulação do crescimento fetal tardio
em gestantes de uma população brasileira.
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INTRODUCTION
Fetal growth is determined by a series of factors: genetic
determinants, growth substrate supply, hormonal factors and
probably others yet unknown. In order to establish the role
each one plays as specific regulating growth factors, recent
investigations have led to impressive progress in this area.
The insulin-like growth factors (IGFs) participate
in the growth and function of almost every organ in
the body. Because of the wide range of their biological
effects and their therapeutic potential in a variety of
clinical disorders, the IGFs have become the focus of
research by an increasing number of investigators(1). The
role of insulin-like growth factors and their binding
proteins during the perinatal period have become an
exciting new area of investigation(2-5).
Insulin-like growth factors 1 (IGF-I) and II (IGF-II)
are mitogenic peptides with growth promoting and tissue
differentiation activity, as well as insulin-like metabolic
effects(6-7). IGFs are found in circulation in association
with binding proteins and very little free IGF (f IGF) is
actually found(8). Since 1974, at least six binding proteins
have been identified (IGFBP-1 to IGFBP-6) but their
functions are not yet very well known. They could act by
modulating IGF action in target tissue but may have other
independent actions(4,8-9). In pregnant women IGFBP-1
is a major product of maternal decidua(3). Up to 26 weeks
of gestation fetal IGFBP-1 is the major binding protein
for IGF-I and after 30 weeks, IGFBP-3 is the main fetal
binding protein(6). IGFBP-1 is inhibitory to the metabolic
and growth effects of IGF-I and is positively related to
insulin secretion and negatively to growth hormone (GH)
secretion(5,8-9). IGFBP-3 is regulated positively by GH
secretion and nutritional status and seems to be correlated
with birth weight(8-9) .
In Brazil, there are few studies on IGFs, and
investigation in this area has become important.
OBJECTIVE
To determine the levels of IGF-I and its binding proteins,
IGFBP-1 and IGFBP-3, in the serum of healthy Brazilian
mothers and their newborns in a population of high
socioeconomic level in the city of São Paulo, Brazil, according
to birth weight of the newborns enrolled in the study.
METHODS
A prospective study of 83 pairs of healthy consecutive
mothers and neonates was carried out. Two groups were
then selected. Group 1: pairs of mothers and their respective
newborns weighing ≥  2500 g at birth (n = 60); and Group
2: pairs of mothers and their respective newborns weighing
< 2500 g at birth (n = 23). The following factors were
considered for maternal inclusion: absence of any obstetrical
complication or disease during pregnancy; and factors for
exclusion were diabetes, hypertension, smoking habit,
alcohol or drug addiction, or any other gestational disease,
according to maternal history.
Only newborns healthy at birth were considered for
inclusion. Factors considered for newborn exclusion:
presence of malformations, the possibility of genetic
or antenatal infectious diseases. The mothers involved
in this study gave birth at the Hospital Israelita Albert
Einstein maternity department, in the city of São Paulo,
Brazil. The study started after approval by the Research
Ethics Committee of the same hospital and obtaining
an informed consent from each mother. The choice of
the 2500 g weight reference value was taken according
to the definition of low birth weight by the World
Health Organization(10).
Ten ml of maternal blood were collected from a dorsal
hand vein a few minutes before delivery. Newborn blood
samples (10 ml) were collected from umbilical cord (both
arterial and venous) immediately after cord clamping. Both
the mother’s and newborn’s samples were collected in
sodium ethylenediaminetetraacetic acid (EDTA) for the
dosages of total IGF-I, f IGF-I, IGFBP- 1 and IGFPB-3.
The samples were stocked at -20°C at the maternity
hospital and the assays were performed at the Laboratory
for Cell and Molecular Endocrinology of the Universidade
de São Paulo, Brazil. Serum levels of IGF-I, fIGF-I,
IGFBP-1, IGFBP-3 were quantitatively measured by
commercial radioimmunoassay (RIA) method (Diagnostic
System Laboratories mc, Webster, USA).
STATISTICAL ANALYSIS
Student’s t test was used to determine the significance of
the difference between means. Multiple regression analysis
was performed considering the auxologic variables as
dependent and biochemical variables as independent.
Values of p < 0.05 were considered statistically significant.
The calculations were processed by the Statsoft mc. 1993
Statistics for Windows version 4.5.
RESULTS
Table 1 shows maternal clinical data, their mean and
standard deviations for both groups. As can be seen in
this table there were no statistical differences between
the mothers of the two groups, according to the
auxologic characteristics here studied.einstein. 2004; 2(2):105-109
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Table 2 shows the clinical characteristics of the
newborns in the two groups. Neonatal auxologic data
were higher in group l as compared to values in group
2 as can be seen on table 2 with statistically significant
differences, since group 2 comprised low birth weight
infants.
Table 1. Clinical characteristic of mothers: mean and range of maternal age
in years, mean and standard deviation of weight before gestation in kilograms
(WBG), weight after gestation in kilograms (WAG), weight gain during
gestation in kilograms (WG), maternal height in meters (MH) in Group 1 and
Group 2
Characteristics Group 1 Group 2 Significance
Age 30 (19-43) 31 (20-43) ns
WBG 58.24 ± 8.63 56.39 ± 5.73 ns
WAG 72.91 ± 10.27 68.96 ± 7.35 ns
WG 14.24 ± 4.60 12.57 ± 3.80 ns
MH 1.64 ± 0.06 1.63 ± 0.06 ns
Table 2. Clinical characteristic of newborns: mean and standard deviation
of newborn weight in grams (NW), newborn length in centimeters (NL),
head circumference in centimeters (HC), chest circumference in centimeters
(CC), gestational age in weeks (GA) and ponderal index (PI). Mean and
Standard deviation (SD ±)
Characteristics Group 1 Group 2 Significance
NW 3184.41 ± 352.80 2108.48 ± 414.09 p < 0.05
NL 49.14 ± 1.65 44.67 ± 2.79 p < 0.05
HC 34.43 ± 1.35 31.13 ± 2.21 p < 0.05
CC 32.5 ± 1.64 27.83 ± 2.75 p < 0.05
GA 38.5 ± 1.32 36.09 ± 2.54 p < 0.05
PI 2.68 ± 0.24 2.35 ± 0.28 p < 0.05
Table 3 displays mean, standard deviation, minimum
and maximum values of plasma concentration of IGF-
I, f IGF-I, IGFBP-3 and IGFBP-1 in groups 1 and 2.
Table 3. Concentration values of IGF-I, f IGF-I, free/total IGF-I(f/t IGF-I),
IGFBP-1 and IGFBP-3 in maternal serum (M) and mixed cord blood (N) in
group 1 and group 2. Mean and Standard deviation (SD±)
Values Group 1 Group 2 Significance
(M) IGF-I 380.84 ± 137.69 232.94 ± 178.26 p < 0.05
(M) f IGF-I 4.37 ± 2.30 7.59 ± 4.90 p < 0.05
(M) f/t IGF-I 1.37 ± 1.00 6.23 ± 8.25 p < 0.05
(M) IGFBP-1 198.31 ± 76.31 164.26 ± 79.59 ns
(M) IGFBP-3 3.54 ± 1.2 3.8 ± 1.15 ns
(N) IGF-I 87.28 ± 63.91 20.83 ± 24.38 p < 0,05
(N) f IGF-I 1.66 ± 2.34 0.38 ± 0.29 p < 0.05
(N) f/t IGF-I 1.81 ± 1.24 2.45 ± 1.10 ns
(N) IGFBP-1 107.81 ± 99.41 168.57 ± 158.81 ns
(N) IGFBP-3 1.20 ± 0.86 0.69 ± 0.18 p < 0.05
When the auxologic variables of the neonates were
considered dependent and the biochemical
independent, multiple regression analysis showed
positive correlation between neonatal IGF-I and
neonatal weight (r = 0.37), length (r = 0.26), ponderal
index (r = 0.32), neonatal head circumference (r = 0.3
1) and neonatal chest circumference (r = 0.24).
Negative correlations were found among neonatal
IGFBP-1, ponderal index (r = -0.23) and gestational
age(r = -0.27), as shown in table 4.
Table 4. Correlation among newborn IGF-I, newborn IGFBP-1 and auxological
data
x axis y axis correlation r Significance
NIGF-I NW positive 0.37 < 0.05
NIGF-I NL positive 0.26 < 0.05
NIGF-I PI positive 0.32 < 0.05
NIGF-I HC positive 0.31 < 0.05
NIGF-I CC positive 0.24 < 0.05
NIGF-I GA positive 0.31 < 0.05
NIGFBP- 1 P1 negative 0.23 < 0.05
NIGFBP-1 GA negative 0.27 < 0.05
Key: N = newborn; NW = newborn weight (g); NL = newborn length (cm);
HC = head circumference (cm); CC = chest circumference (cm); GA =
gestational age (weeks); PI = ponderal index (g/cm3)
When neonatal biochemical variables were
considered as dependent and maternal biochemical as
independent, the following correlations were found:
maternal f IGF-I and the f/t relation of the newborn (r
= 0.54); maternal f IGF-I and neonatal IGFBP-3 (r =
0.27); maternal IGFBP-1 and neonatal IGF-I (r = 0.30);
maternal IGFBP-1 and neonatal IGFBP-3 (r = 0.26)
and maternal IGFBP-3 and neonatal IGF-I (r = 0.30)
(p < 0.05) as shown in table 5.
Table 5. Correlation among maternal IGF-I, IGFBP-1 , IGBFP-3 and newborn
IGF-I, f/t, IGFBP- 1, IGFBP-3
x axis y axis correlation r Significance
MIGF-I Nf/t positive 0.54 < 0.05
MIGF-1 NIGFBP-3 negative 0.27 < 0.05
MIGFBP-1 NIGF-I negative 0.30 < 0.05
MIGFBP-1 NIGFBP-3 negative 0.26 < 0.05
MIGFBP-3 NIGF-I negative 0.30 < 0.05
MIGFBP-3 NIGFBP-1 positive 0.24 < 0.05
M1GFBP-3 NIGFBP-3 negative 0.39 < 0.05
M = maternal; N = newborn
DISCUSSION
Many controversies are still present relating to the role
of IGFs on fetal growth. It is well known that certain
maternal diseases, such as severe pre-eclampsia or
undernutrition, and alcohol ingestion or cigarette
smoking can alter maternal IGF serum concentrations
and its binding proteins(4,11-13). In view of this evidence,
in the present study we considered only healthy mothers
and their newborns, differing only by birth weight, to
investigate their IGF-I, IGFBP-1 and IGFBP-3 serum
concentrations. The clinical characteristics of mothers
in group 1 were not different from group 2 but the
parameters of the newborns in group 1 were
significantly different from those in group 2, since this
latter group comprised low birth weight infants born
from apparently healthy mothers. In the present study,
maternal IGF-I serum concentration in group 1 was
significantly higher than that of group 2 and neonatal
IGF-I cord blood concentration was significantly highereinstein. 2004; 2(2):105-109
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in group 1 than in group 2. Clapp et al. reported, in
2004, a strong linear correlation between an increase
in maternal IGF-I levels from 16 to 32 weeks of
gestation and birth weight, neonatal fat mass and
placental mass at term; however, as emphasized by these
authors, this finding may not imply causality(14).
Direct evidence of IGF role in fetal growth clearly
exists in rodents. Transgenic homozygotic mice for
disfunctioning allele of IGF-I and IGF-II receptors
show an important delay in intrauterine, fetal and
postnatal growth(15). In the human neonate there are
data suggesting a correlation between IGF-I and
growth. Foley et al., in 1980, found reduced IGF levels
in cord serum from infants with intrauterine growth
retardation(16). Lassare et al., in 1991, found levels of
fetal IGF-I positively correlated to neonatal
anthropometric data(17). Others studies also report
similar findings(14,18-22). However, many investigators have
found IGF-1 levels in both umbilical artery and venous
blood inversely related to birth weight or have not
found any correlation between IGF-I cord serum levels
and birth weight(2,6). In the present paper, it was found
that neonatal IGF-I correlated positively with birth
weight, neonatal height, ponderal index, head
circumference, chest circumference and gestational age,
all these findings corroborating the data pointing to
the fact that IGF-I plays an active role in the regulation
of fetal growth. It was also found that neonatal f IGF-
I was significantly higher in group 1 than in group 2.
In the present study, maternal IGFBP-1 in group 1
and 2 did not show statistically significant differences,
implying probably that maternal IGFBP-1 is not part
of normal placental function as pointed out by Holmes
et al.(23), in 2000, although it is interesting to observe
that maternal IGFPB-1 presented higher levels in the
low birth weight group than in group 1; however, there
were no statistical significant differences. In their
paper, Holmes et al.(23) emphasized that high IGFBP-1
concentrations may reduce the availability of maternal
IGF to the placenta adversely affecting fetal growth.
Vatten et al.(24), in 2002, found that high levels of
IGFBP-1 were associated with low birth weight and
reduced length.
A negative correlation between maternal IGFBP-1
and neonatal IGF-I, as well as a negative correlation
between neonatal IGFBP-1 and ponderal index were
found. These findings are also compatible with the
suggestion that IGFBP-1 may have an inhibitory effect
on the action of IGFs(25-26).
Other apparently peculiar findings in this study were
the significant higher levels of maternal f IGF-I in
group 2 than in group 1. It has been demonstrated
that protease activity for IGFBP-3 is increased in
uteroplacental insufficiency(27). Part of the present
sample in group 2 consisted of fetuses with intrauterine
growth restriction; therefore, one could speculate that,
in group 2 of this study, proteases could be acting on
IGFBP-3, promoting higher availability of the
biologically active IGF-I, that is, free IGF-I, as if trying
to improve fetal growth.
Statistically significant differences were not found
between maternal IGFBP-3 in both groups but a
negative correlation among maternal IGFBP-3,
neonatal IGF-1 and neonatal IGFBP-1 was found. The
positive correlation between maternal IGF-I and
neonatal ratio free IGF-I/total IGF-I (f/t) and the
negative correlation between maternal IGFBPs with
neonatal IGF-I could be evidence of maternal
contribution for IGF-I availability to the fetus. These
data are showing particularly important roles for IGF-
I, and probably IGFBP-3 in regulating fetal growth at
term.
CONCLUSION
The findings of this study suggest that IGF-I and
IGFBP-1 and IGFBP-3 play a role in regulation of late
fetal growth, being associated with fetal size in normal
Brazilian pregnant women.
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